Covered recipient · General Payments record
ERICA L MAYER
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$85,449.17
52 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $81,677.91 | 25 |
| Food and Beverage | $1,894.20 | 19 |
| Travel and Lodging | $1,833.81 | 7 |
| Education | $43.25 | 1 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $21,000.00 | 4 |
| AstraZeneca Pharmaceuticals LP | $15,005.60 | 10 |
| Genentech, Inc. | $14,439.11 | 5 |
| Novartis Pharmaceuticals Corporation | $11,600.34 | 6 |
| AstraZeneca UK Limited | $7,664.02 | 11 |
| F. Hoffmann-La Roche AG | $6,150.00 | 3 |
| Eli Lilly and Company | $5,138.00 | 10 |
| Genentech USA, Inc. | $4,117.61 | 2 |
| E.R. Squibb & Sons, L.L.C. | $334.49 | 1 |
Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ERICA L MAYER
NPI 1336121789 · CMS profile ID 196667
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
BOSTON, MA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1336121789?year=2025&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ERICA L MAYER, NPI 1336121789, CMS profile ID 196667. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1336121789?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). ERICA L MAYER, NPI 1336121789, CMS profile ID 196667. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1336121789?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- ERICA L MAYER, NPI 1336121789, CMS profile ID 196667, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1336121789?year=2025&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
52 matching records · $85,449.17 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–52 of 52.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| AstraZeneca UK Limited | $685.00 | 03/10/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202985906 | CMS |
| AstraZeneca Pharmaceuticals LP | $4,920.00 | 02/07/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206593500 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $2,882.90 | 4 |
| PY2025 | Principal investigator | $5,404,681.24 | 238 |
| PY2024 | Recipient | $534,088.94 | 2 |
| PY2024 | Principal investigator | $11,732,974.20 | 269 |
| PY2023 | Recipient | $3,821.82 | 3 |
| PY2023 | Principal investigator | $7,889,174.32 | 200 |
| PY2022 | Recipient | $1,270.00 | 2 |
| PY2022 | Principal investigator | $6,761,889.59 | 143 |
| PY2021 | Principal investigator | $5,774,214.47 | 95 |
| PY2020 | Principal investigator | $7,800,717.44 | 500 |
| PY2019 | Principal investigator | $6,264,661.64 | 577 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
242 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | PFIZER INC. | $500.00 | 12/18/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721431 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 12/18/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721433 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 12/18/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721443 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 12/18/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721573 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 12/18/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721625 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 12/18/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721629 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 12/18/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721637 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 12/18/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721691 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 12/18/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721693 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 12/18/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721699 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 12/18/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721703 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 12/18/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721765 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 12/18/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721805 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 12/18/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721811 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 12/18/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721813 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 12/18/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721825 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 12/18/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721875 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 12/18/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721883 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 12/18/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721897 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 12/18/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721927 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 12/18/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721935 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 12/18/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721945 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 12/18/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722013 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 12/18/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722069 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 12/18/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722071 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 12/18/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722081 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 12/18/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722085 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 12/18/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722135 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 12/18/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722143 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 12/18/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722145 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 12/18/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722181 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 12/18/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722199 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 12/18/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722201 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 12/18/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722215 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 12/18/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722275 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 12/18/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722416 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $6,860.06 | 12/15/2025 | Non-covered Recipient Entity DANA-FARBER/MASS GENERAL BRIGHAM CANCER CARE, INC | ALI-1201 | No dispute reported | 06/30/2026 | 1251753972 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $17,865.16 | 12/12/2025 | Non-covered Recipient Entity Dana Farber Cancer Institute | Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) alone and in combination with pembrolizumab in subjects with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative, locally advanced and unresectable or metas | No dispute reported | 06/30/2026 | 1235997774 |
| Recipient | F. Hoffmann-La Roche AG | $503.68 | 12/12/2025 | Covered Recipient Physician | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211535681 |
| Recipient | F. Hoffmann-La Roche AG | $292.89 | 12/12/2025 | Covered Recipient Physician | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211535685 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $1,475.82 | 12/03/2025 | Non-covered Recipient Entity DANA FARBER CANCER INSTITUTE, INC | A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole | No dispute reported | 06/30/2026 | 1185537978 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $11,575.80 | 11/14/2025 | Non-covered Recipient Entity DANA-FARBER/MASS GENERAL BRIGHAM CANCER CARE, INC | ALI-1201 | No dispute reported | 06/30/2026 | 1251753978 |
| Recipient | F. Hoffmann-La Roche AG | $1,225.57 | 10/18/2025 | Covered Recipient Physician | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211535676 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 10/17/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721631 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 10/17/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721777 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 10/17/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721891 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 10/17/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722554 |
| Principal investigator 1 | Genentech, Inc. | $11,508.00 | 10/16/2025 | Non-covered Recipient Entity DANA FARBER MASS GENERAL BRIGHAM CANCER CARE INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211594523 |
| Principal investigator 1 | Genentech, Inc. | $3,000.00 | 10/16/2025 | Non-covered Recipient Entity DANA FARBER MASS GENERAL BRIGHAM CANCER CARE INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211594527 |
| Principal investigator 1 | Genentech, Inc. | $71,895.00 | 10/16/2025 | Non-covered Recipient Entity DANA FARBER MASS GENERAL BRIGHAM CANCER CARE INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211594531 |
| Principal investigator 1 | Genentech, Inc. | $2,275.00 | 10/16/2025 | Non-covered Recipient Entity DANA FARBER MASS GENERAL BRIGHAM CANCER CARE INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211594535 |
| Principal investigator 1 | Genentech, Inc. | $16,410.00 | 10/16/2025 | Non-covered Recipient Entity DANA FARBER MASS GENERAL BRIGHAM CANCER CARE INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211594538 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721427 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721429 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721435 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721437 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721439 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721441 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721567 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721569 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721571 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721575 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721577 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721579 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721581 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721583 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721627 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721633 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721635 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721639 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721641 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721689 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721695 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721697 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721701 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721705 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721707 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721709 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721711 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721759 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721761 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721763 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721767 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721769 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721771 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721773 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721775 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721807 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721809 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721815 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721823 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721827 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721877 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721879 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721881 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721885 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721887 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721889 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721893 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721895 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721929 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721931 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721933 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721943 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721947 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721991 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721993 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721995 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721997 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721999 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722001 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722009 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722011 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722073 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722083 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722125 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722127 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722129 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722131 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722133 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722147 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722203 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722211 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722213 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722261 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722263 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722265 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722273 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722277 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722362 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722364 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722366 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722406 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722408 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722418 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722420 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722550 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722552 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722562 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722564 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722566 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $36,850.00 | 09/12/2025 | Non-covered Recipient Entity DANA FARBER PARTNERS CANCER CARE | Capivasertib plus Palbociclib plus Fulvestrant for HR/HER2 Advanced Breast Cancer CAPItello 292. | No dispute reported | 06/30/2026 | 1185537972 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $16,967.37 | 08/15/2025 | Non-covered Recipient Entity DANA-FARBER/MASS GENERAL BRIGHAM CANCER CARE, INC | ALI-1201 | No dispute reported | 06/30/2026 | 1251753974 |
| Principal investigator 1 | Genentech, Inc. | $4,500.00 | 07/17/2025 | Non-covered Recipient Entity DANA FARBER MASS GENERAL BRIGHAM CANCER CARE INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211594490 |
| Principal investigator 1 | Genentech, Inc. | $143,790.00 | 07/17/2025 | Non-covered Recipient Entity DANA FARBER MASS GENERAL BRIGHAM CANCER CARE INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211594499 |
| Principal investigator 1 | Genentech, Inc. | $22,254.00 | 07/17/2025 | Non-covered Recipient Entity DANA FARBER MASS GENERAL BRIGHAM CANCER CARE INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211594501 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $17,200.00 | 07/04/2025 | Non-covered Recipient Entity Dana-Farber Cancer Institute, Clinical Research Laboratory | Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) alone and in combination with pembrolizumab in subjects with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative, locally advanced and unresectable or metas | No dispute reported | 06/30/2026 | 1235997764 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $45,303.84 | 06/27/2025 | Non-covered Recipient Entity JOHN HOPKINS UNIVERSITY | 0000000000000000000000000000000000000000000000000000000000000000214387 | No dispute reported | 06/30/2026 | 1192160818 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 06/23/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722688 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 06/23/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228724620 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 06/23/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228784243 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 06/23/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228784383 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 06/23/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228784526 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 06/23/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228785002 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 06/23/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228785338 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 06/23/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228785496 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 06/23/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228785648 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 06/23/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228785688 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 06/23/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228786841 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 06/23/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228787120 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 06/23/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228787142 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 06/23/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228787150 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 06/23/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228787453 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 06/23/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228787794 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 06/23/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228787872 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 06/23/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228788110 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 06/23/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228788206 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 06/23/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228789041 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 06/23/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228789254 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $181,215.36 | 06/20/2025 | Non-covered Recipient Entity JOHN HOPKINS UNIVERSITY | 0000000000000000000000000000000000000000000000000000000000000000214387 | No dispute reported | 06/30/2026 | 1192160831 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $45,303.84 | 06/19/2025 | Non-covered Recipient Entity JOHN HOPKINS UNIVERSITY | 0000000000000000000000000000000000000000000000000000000000000000214387 | No dispute reported | 06/30/2026 | 1192160822 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $45,303.84 | 06/18/2025 | Non-covered Recipient Entity JOHN HOPKINS UNIVERSITY | 0000000000000000000000000000000000000000000000000000000000000000214387 | No dispute reported | 06/30/2026 | 1192162421 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $57,350.00 | 06/16/2025 | Non-covered Recipient Entity DANA-FARBER/MASS GENERAL BRIGHAM CANCER CARE, INC | ALI-1201 | No dispute reported | 06/30/2026 | 1251753976 |
| Principal investigator 1 | Genentech, Inc. | $816.00 | 06/11/2025 | Non-covered Recipient Entity DANA FARBER MASS GENERAL BRIGHAM CANCER CARE INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211594322 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $45,303.84 | 06/06/2025 | Non-covered Recipient Entity JOHN HOPKINS UNIVERSITY | 0000000000000000000000000000000000000000000000000000000000000000214387 | No dispute reported | 06/30/2026 | 1192160235 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 05/30/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228720101 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 05/30/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228784262 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 05/30/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228785192 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 05/30/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228787192 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 05/30/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228787772 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 05/30/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228788027 |
| Principal investigator 1 | Genentech, Inc. | $1,224.00 | 05/05/2025 | Non-covered Recipient Entity DANA FARBER MASS GENERAL BRIGHAM CANCER CARE INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211594325 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $65,100.00 | 04/30/2025 | Covered Recipient Teaching Hospital Dana-Farber Cancer Institute | Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) alone and in combination with pembrolizumab in subjects with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative, locally advanced and unresectable or metas | No dispute reported | 06/30/2026 | 1236001379 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 04/29/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228719629 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 04/29/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228784340 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 04/29/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228785960 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 04/29/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228789411 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $783,497.26 | 04/23/2025 | Non-covered Recipient Entity DANA FARBER CANCER INSTITUTE INC. | A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole | No dispute reported | 06/30/2026 | 1185537980 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $90,607.68 | 04/22/2025 | Non-covered Recipient Entity JOHN HOPKINS UNIVERSITY | 0000000000000000000000000000000000000000000000000000000000000000214387 | No dispute reported | 06/30/2026 | 1192160800 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $23,588.76 | 04/22/2025 | Non-covered Recipient Entity JOHN HOPKINS UNIVERSITY | 0000000000000000000000000000000000000000000000000000000000000000214387 | No dispute reported | 06/30/2026 | 1192162413 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $618,536.00 | 04/04/2025 | Non-covered Recipient Entity JOHNS HOPKINS UNIV | A PHASE II STUDY OF NIRAPARIB WITH DOSTARLIMAB THERAPY AS NEOADJUVANT | No dispute reported | 06/30/2026 | 1192162445 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 04/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228784269 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 04/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228784530 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 04/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228784588 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 04/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228784882 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 04/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228785350 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 04/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228787628 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 04/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228788569 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 04/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228789395 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 04/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228789730 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 04/02/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228789773 |
| Recipient | E.R. Squibb & Sons, L.L.C. | $860.76 | 03/28/2025 | Covered Recipient Physician | Phase 1b/2 Open-label Trial of 225Ac-DOTATATE (RYZ101) in Subjects With Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, Locally Advanced and Unresectable or Metastatic Breast Cancer Expressing Somatostatin | No dispute reported | 06/30/2026 | 1236002143 |
| Principal investigator 1 | Genentech, Inc. | $32,909.00 | 03/24/2025 | Non-covered Recipient Entity DANA FARBER MASS GENERAL BRIGHAM CANCER CARE INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211594320 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 03/12/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722954 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 03/12/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228784522 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 03/12/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228785834 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 03/12/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228786308 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 03/12/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228786860 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 03/12/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228787358 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 03/12/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228787620 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 03/12/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228787754 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 03/12/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228787758 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 03/12/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228788727 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 03/12/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228788740 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 03/12/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228789383 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 03/12/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228789392 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 03/12/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228789415 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 03/12/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228790052 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $135,911.52 | 03/11/2025 | Non-covered Recipient Entity JOHN HOPKINS UNIVERSITY | 0000000000000000000000000000000000000000000000000000000000000000214387 | No dispute reported | 06/30/2026 | 1192160810 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $35,383.14 | 03/07/2025 | Non-covered Recipient Entity JOHN HOPKINS UNIVERSITY | 0000000000000000000000000000000000000000000000000000000000000000214387 | No dispute reported | 06/30/2026 | 1192160814 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,237,073.00 | 03/05/2025 | Non-covered Recipient Entity JOHNS HOPKINS UNIV | A PHASE II STUDY OF NIRAPARIB WITH DOSTARLIMAB THERAPY AS NEOADJUVANT | No dispute reported | 06/30/2026 | 1192162440 |
| Principal investigator 1 | PFIZER INC. | $569,887.95 | 02/24/2025 | Non-covered Recipient Entity DANA FARBER PARTNERS CANCER CARE | PALBOCICLIB AFTER CDK AND ENDOCRINE THERAPY PACEA RANDOMIZED PHASE II STUDY OF FULVESTRANT PALBOCICLIB AND AVELUMAB FOR ENDOCRINE PRETREATED ERHER2 METASTATIC BREAST CANCER | No dispute reported | 06/30/2026 | 1228778804 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $90,607.68 | 02/06/2025 | Non-covered Recipient Entity JOHN HOPKINS UNIVERSITY | 0000000000000000000000000000000000000000000000000000000000000000214387 | No dispute reported | 06/30/2026 | 1192160240 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $226,519.20 | 02/05/2025 | Non-covered Recipient Entity JOHN HOPKINS UNIVERSITY | 0000000000000000000000000000000000000000000000000000000000000000214387 | No dispute reported | 06/30/2026 | 1192162427 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $35,383.14 | 02/04/2025 | Non-covered Recipient Entity JOHN HOPKINS UNIVERSITY | 0000000000000000000000000000000000000000000000000000000000000000214387 | No dispute reported | 06/30/2026 | 1192160827 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $23,588.76 | 02/04/2025 | Non-covered Recipient Entity JOHN HOPKINS UNIVERSITY | 0000000000000000000000000000000000000000000000000000000000000000214387 | No dispute reported | 06/30/2026 | 1192162417 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $70,766.28 | 02/04/2025 | Non-covered Recipient Entity JOHN HOPKINS UNIVERSITY | 0000000000000000000000000000000000000000000000000000000000000000214387 | No dispute reported | 06/30/2026 | 1192162436 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 01/30/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228784518 |
| Principal investigator 1 | PFIZER INC. | $600.00 | 01/30/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228785009 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 01/30/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228785021 |
| Principal investigator 1 | PFIZER INC. | $600.00 | 01/30/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228785119 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 01/30/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228785636 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 01/30/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228786305 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 01/30/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228787959 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 01/30/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228788067 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 01/30/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228788931 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 01/30/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228789089 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 01/30/2025 | Non-covered Recipient Entity Dana FarberMass General Brigham CancerCare Inc | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228789427 |
| Principal investigator 1 | AstraZeneca UK Limited | $87,248.18 | 01/28/2025 | Non-covered Recipient Entity DANA FARBER CANCER INSTITUTE, INC | CAMBRIA-2 A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease | No dispute reported | 06/30/2026 | 1185537974 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $45,303.84 | 01/28/2025 | Non-covered Recipient Entity JOHN HOPKINS UNIVERSITY | 0000000000000000000000000000000000000000000000000000000000000000214387 | No dispute reported | 06/30/2026 | 1192160805 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $187,629.86 | 01/24/2025 | Non-covered Recipient Entity DANA FARBER PARTNERS CANCER CARE | A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole | No dispute reported | 06/30/2026 | 1185537976 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $181,215.36 | 01/10/2025 | Non-covered Recipient Entity JOHN HOPKINS UNIVERSITY | 0000000000000000000000000000000000000000000000000000000000000000214387 | No dispute reported | 06/30/2026 | 1192162432 |